Results: HeL and especially PHeL most commonly show a diffuse large B-cell lymphoma phenotype and have a poor prognosis (median survival of seven months). PHeL is strongly associated with human immunodeficiency virus infection (12/16 patients).

Conclusions: Image-guided FNA with immediate evaluation is a reliable means to obtain diagnostic material and triage for ancillary tests.
Hepatic involvement by hematolymphoid malignancies (hepatic lymphoma [HeL] ) is a relatively common presentation of extranodal disease spread. In rare instances, lymphomas may also involve the liver exclusively (primary hepatic lymphomas [PHeL] ). The diagnosis of HeL and especially PHeL may be challenging, owing to an often low index of suspicion, nonspecific patient presentations, and often nonspecific radiologic findings. Nevertheless, demonstrating liver involvement by lymphoproliferative disease is important not only for diagnosis but also for staging purposes and treatment planning.
Laparoscopy-assisted liver biopsy has been traditionally used as a useful technique to establish hepatic involvement by lymphoproliferative disease, with a reported specificity of 100% in cases of visible (mass-forming) liver lesions. 1 In the past decade, however, laparoscopic staging of lymphomas has been largely replaced by new imaging techniques.
Upon completion of this activity you will be able to:
• describe the clinical situations in which hepatic lymphoma is most likely to occur.
• list differential diagnostic entities for "small round blue cells" within the liver and compare their cytomorphologic features.
• compare the common phenotypes of primary and secondary hepatic lymphomas.
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Questions appear on p 142. Exam is located at www.ascp.org/ajcpcme.
Positron emission tomography/computed tomography (CT) and magnetic resonance imaging (MRI), in particular, have been proven to be highly sensitive in detecting extranodal disease. 2, 3 Despite these advances, several studies have shown high rates of clinical and radiographic misdiagnosis prior to final pathologic examination of tissues, especially in the diagnosis of PHeL. 4, 5 With the increase in utilization of imaging techniques, the role of image-guided fine-needle aspiration (FNA) in liver lesions has also evolved. Owing to such advances, pathologists are now often faced with the challenge of diagnosing smaller lesions with less tissue. The effective diagnostic yield of imageguided liver FNA depends on many factors, including the skill and experience of the radiologist and cytopathologist, lesion size, and appropriate use of additional ancillary studies (immunohistochemistry [IHC], molecular modalities, flow cytometry, etc). In addition, hematolymphoid malignancies are a heterogeneous group of diseases with a variety of cytomorphologic appearances. Findings of large monotonous, discohesive cells with a high nuclear-cytoplasmic ratio, prominent nucleoli, the presence of lymphoglandular bodies, crush artifact, and smearing of the nuclear content in a clinical setup of single or multiple hypodense liver lesions should suggest a potential diagnosis of HeL. Therefore, immediate (on-site) evaluation of the aspirate sample by a cytopathologist or experienced cytotechnologist can facilitate the accurate diagnosis and ensure appropriate triage of the specimen for important ancillary tests. Herein we describe the clinicopathologic findings of 32 patients diagnosed with HeL by image-guided FNA, the largest retrospective series of HeL and PHeL to our knowledge.
Materials and Methods
Following institutional review board approval, a 15-year (1996-2011) by a cytopathologist in each case. Pathology slides and ancillary studies (flow cytometry and IHC) were reviewed to confirm the diagnosis. In addition, demographics (race, age, and sex), laboratory data (HIV serology, CD4 counts, viral loads, and lactate dehydrogenase measures), imaging studies (CT and MRI), and clinical information were extracted from electronic patient medical records ❚Table 1❚. Patient outcome was recorded, including follow-up time and whether the patient was alive or deceased (including discharge to hospice/palliative care service) at the time of last follow-up. Image-guided FNA cases with the final diagnosis of lymphoproliferative disease, malignant lymphoma, or suspicious for malignant lymphoma were selected. These HeL cases were then divided into PHeL and secondary HeL (SHeL). Cases were considered PHeL when the patient had no history of prior or subsequent lymphoma diagnosis, no other biopsyproven hematolymphoid neoplasm at a nonhepatic location, and no clinical concern for hematolymphoid malignancy elsewhere in the body. This is consistent with PHeL, as defined by some prior studies. 4, 6 However, there is no consensus opinion on the definition of PHeL, and some studies have used less stringent criteria, including mainly hepatic-derived symptoms without lymphadenopathy and leukemic involvement, 7 as well as inclusion of those with perihepatic nodal disease and bone marrow involvement. 8 Clinical and radiologic characteristics between the PHeL and SHeL groups were compared along with diagnostic modalities used ❚Table 2❚. P values between these two groups were calculated by c 2 analysis for discrete variables and by a two-tailed t test for continuous variables, with differences considered significant with P < .05. Final diagnosis in each case was also compared between both groups to show diagnostic trends ❚Table 3❚.
Results
Thirty-two cases of hepatic lymphoma diagnosed by FNA were identified on review of two institutions from 1996 through 2011. Half of the cases were identified in an inner-city public hospital and the other half in an academic tertiary care center. Case-by-case patient data are displayed in Table 1 .
The mean patient age at diagnosis was 50.8 years, and 75% (24/32) of patients were male. Patients were primarily of African American (15/32, 47%) and white (13/32, 41%) race. The most common clinical complaints were abdominal pain, fatigue, weight loss, nausea and vomiting, fever, headache, rash, neuropathy, and jaundice (data not shown). In seven patients, the liver lesions were identified during surveillance imaging following the diagnosis of nodal lymphoma. Twothirds of the patients had multiple liver masses (21/31, 68%), while one-third had a single mass (10/31, 32%). Interestingly, 12 (75%) of 16 patients with PHeL had multiple liver lesions, and all of such patients were HIV infected. There was no significant difference in the mean diameter of the largest liver lesions in primary or secondary liver lymphomas. Ancillary studies were used as an adjunct to diagnosis in most cases, including flow cytometry in 20 of 32 cases with diagnostic findings in 70%. Immunohistochemistry was used in 24 of 32 cases. Patient demographics as well as radiographic and diagnostic modality characteristics are summarized in Table 2 .
The most common HeL diagnosis was diffuse large B-cell lymphoma (DLBCL), comprising approximately onethird of the cases (12/32) ( Table 3 ) ❚Figure 1❚. Other lymphoid malignancies included plasma cell myeloma (4/32), B-cell lymphoma not otherwise specified (NOS) (3/32), and Hodgkin lymphoma (3/32). There was one case of each of the following: Burkitt lymphoma, hairy cell leukemia, human herpesvirus 8 (HHV-8)-associated effusion lymphoma, posttransplant lymphoproliferative disorder (PTLD), and T-cell lymphoma. Five cases were diagnosed as "suspicious for lymphoma" due to extensive necrosis or insufficient material 
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Discussion
Accurate Diagnosis of HeL
This retrospective study summarizes the clinicopathologic characteristics of patients diagnosed with HeL, with a comparison of PHeL and SHeL. PHeL, defined as extranodal lymphoma of the liver not involving any other organ, is particularly rare and therefore often unexpected, representing approximately 0.016% of non-Hodgkin lymphomas. 7 The initial clinical presentation of a patient with HeL is usually characterized by nonspecific symptoms, including nausea, abdominal pain, and jaundice, often of short duration. Rarely, fulminant liver failure can occur, as has been reported with PHeL. 9, 10 This study found similar nonspecific clinical presentations, with a predominance of abdominal pain, weight loss, and jaundice (data not shown). Demographically, patients with PHeL often showed HIV infection (12/16), and those with SHeL often had a known history of hematolymphoid malignancy (10/16).
Imaging findings in HeL are not entirely specific and often mimic metastatic carcinoma. 5, 11 HeL can present as a single lesion, multiple nodules, or diffuse liver involvement. 5 When distinct lesions are seen, they tend to be hypointense on CT and T1-weighted MRI ❚Image 1❚, with slight enhancement seen on T2-weighted MRI. 11 Previous studies have shown that PHeL is more likely to present as a single mass, often more than 4 cm, while SHeL tends to result in multiple liver masses. 5 Most patients diagnosed with HeL in this study had multiple liver masses (21/32, 65%). In contrast to the imaging findings in previous studies, 5, 12 imaging data from our study showed a higher incidence of multiple liver lesions in PHeL than in SHeL (12/16 vs 9/16), but this difference did not reach statistical significance. This study's findings suggest that in The remaining 16 patients demonstrated secondary liver involvement by lymphoma. Ten (64%) of these 16 patients had a hepatic recurrence of a previously diagnosed lymphoma. Five patients had biopsy-proven lymphoma of distant lymph nodes, and four patients showed bone marrow involvement by lymphoma. Other sites of concomitant involvement included the head and neck, bone, kidney, lung, soft tissue, and pericardial and pleural fluids. Four of the 16 patients in the SHeL group were HIV positive. Three were infected with HCV, and three were chronically infected with HBV. Specific diagnoses in SHeL showed less predominance of DLBCL than those of PHeL, with only two of 16 aspirations yielding DLBCL. Other diagnoses consisted of Hodgkin lymphoma (3/16), plasma cell myeloma (3/16), B-cell lymphoma NOS (2/16), PTLD (1/16), hairy cell leukemia (1/16), and HHV-8-induced effusion lymphoma (1/16). Three cases were diagnosed as "suspicious for lymphoma."
Results were also tabulated by infection status regarding HIV, HCV, and HBV ❚Table 4❚. As previously stated, 75% of patients with PHeL were known to be HIV infected, and all patients within this subset had multiple liver lesions. Conversely, in patients who were HIV negative or HIV unknown with PHeL, liver lesions were all single. In addition, most PHeL among HIV-infected individuals was due to B-cell lymphoma (DLBCL, n = 7; B-cell lymphoma NOS, n = 1; Burkitt lymphoma, n = 1; and suspicious for B-cell lymphoma, n = 2). In the group of SHeL, only one-fourth of the patients were known to be HIV positive.
Overall median follow-up in patients last known alive was three months. In all, 12 patients were known to have died or transferred to a hospice at last follow-up (six with PHeL and six with SHeL). Overall median survival was seven months and was not significantly different between PHeL and SHeL.
❚Table 4❚ Diagnosis by Viral Infection Status Between PHeL and SHeL a
the clinical setting of an immunocompromised patient or a patient with a previous diagnosis of lymphoma, the diagnosis of HeL should be considered, especially in the setting of multiple liver lesions on imaging studies. Of interest, HIVinfected patients undergoing image-guided liver FNA in one of our institutions were diagnosed with lymphoma (PHeL and SHeL combined) 45% of the time. This, surprisingly, represented the most common liver FNA diagnosis in this population ❚Table 5❚. Previous studies have demonstrated that image-guided biopsy is a safe method, with a high diagnostic yield in the clinical workup of liver lesions. 8 In recent years, minimally invasive image-guided FNA has become popular in assessing deep-seated lesions of solid organs. Rapid onsite assessment of specimen adequacy is a valuable tool for further diagnostic workup of HeL, owing to its ability to triage additional ancillary testing when HeL is unexpectedly encountered. Immediate evaluation allowed for most (63%) cases in this study to be submitted for flow cytometric analysis, assisting in obtaining an accurate final diagnosis.
Recognizing the cytomorphologic features of a hematolymphoid malignancy is critical at the time of immediate evaluation for these reasons. Findings of monotonous, discohesive cells with a high nuclear-cytoplasmic ratio are typical and should raise the possibility of a diagnosis of HeL to cytopathologists ❚Image 2❚. The presence of lymphoglandular bodies (cytoplasmic remnants of lymphoid cells) may also be helpful in the recognition of HeL. Additional diagnostic considerations in an aspirate sample from a liver mass that is entirely composed of relatively monotonous cells with a high nuclear-cytoplasmic ratio include neuroendocrine neoplasms, metastatic melanoma, hepatoblastoma, small cell variant of hepatocellular carcinoma, and metastatic neuroblastoma. Characteristic cytomorphologic features of these tumors are summarized in ❚Table 6❚. 13 
Pathologic and Epidemiologic Characteristics of HeL
HeL cases in this study showed a wide range of ages at diagnosis (range, 21-89 years) and a marked male predominance (3:1 male to female). Overall median survival was poor (seven months), although follow-up was challenging in this study's patient population (median follow-up of three months in patients last known alive). There was a significant rate of ❚Image 1❚ Serial computed tomography images from a patient with a diagnosis of primary hepatic lymphoma, diffuse large B-cell lymphoma type. Multiple hypodense lesions are identified within the liver parenchyma (arrows). 16, 17 Concomitant HIV infection is of uncertain prognostic significance. 8 concomitant HIV infection (50%). The rate of HIV infection was significantly higher in the PHeL group than in the SHeL group (75% vs 25%, n = .005). Concomitant chronic HBV and HCV infection was identified in 16% of diagnosed patients each. PHeL showed a marked predominance of DLBCL as a final diagnosis (9/16 patients), while SHeL showed a more heterogeneous group of final diagnoses. PHeL is sufficiently rare that definitive disease management is not well defined, and its etiology is currently unknown. 4, 14 Previous studies have shown that most PHeL
A B E D C ❚Image 2❚ Morphologic findings in primary hepatic lymphoma, diffuse large B-cell lymphoma type. Cytomorphologic findings include groups of monotonous, discohesive, hyperchromatic cells with crush artifact (A, Diff-Quick, ×400; B, PAP, ×400X). H&E staining of a representative cell block showed sheetlike growth of large, atypical hematolymphoid cells (C, ×400). Immunohistochemical evaluation of this case showed diffuse CD20 staining (D, ×400) in the atypical lesional cells with CD3 negativity (E, ×400), consistent with B-cell lymphoma.
HCV and HBV in all HeL. No significant differences were identified in viral hepatitis infection prevalence between PHeL and SHeL.
Conclusions
This study shows that HeL can be accurately diagnosed and classified by image-guided FNA, especially when combined with ancillary studies. Clinical suspicion for HeL should be raised with the presence of multiple hypodense hepatic lesions in immunocompromised patients or in patients with a history of hematolymphoid malignancies. The combination of cytomorphologic features, immunohistochemical stains, and flow cytometry was able to render a final diagnosis in all our cases. On-site evaluation of the specimen helps in obtaining adequate samples for further diagnostic studies and plays a critical role in the subclassification of lymphomas.
Etiologically, HeL (especially PHeL) is most commonly a large B-cell lymphoma and has a poor prognosis, with overall median survival of seven months in this study. PHeL often presents in immunocompromised patients and frequently develops in HIV-infected individuals with low CD4 counts.
To our knowledge, this study represents the largest case series of PHeL cases diagnosed by FNA in the literature. In all, our data regarding PHeL cases are largely consistent with previous studies. Despite poor patient follow-up, median survival for patients with PHeL in this study was six months, falling within the reported range of previous studies. 5, 8, 15 Survival was not significantly different from SHeL. The primary final diagnosis was most commonly large B-cell lymphoma, also consistent with numerous studies. 4, [6] [7] [8] 14, 15, 18 Interestingly, the incidence of large B-cell lymphoma dropped precipitously in the SHeL group, perhaps indicating a unique disease etiology for PHeL.
A strong correlation with concomitant HIV infection in PHeL is also identified in this study. In general, HIV-related lymphoma is a not-uncommon disease and is a well-known complication of advanced-stage HIV infection. HIV-related lymphomas are usually high-grade B-cell non-Hodgkin lymphomas that often present with extranodal disease. 19, 20 While the incidence of liver involvement in patients with HIV-related non-Hodgkin lymphoma is reported to range from 26% to 54%, [21] [22] [23] PHeL remains decidedly rare. To our knowledge, this study shows a much higher rate of concomitant HIV infection in PHeL (75%) than in other studies to this point, which have reported HIV infection as high as 41% in patients with PHeL. 8 This high level of concomitant HIV infection may be the result of selection bias, in part, since 12 cases of PHeL in this study came from an innercity public hospital with a high volume of HIV-positive patients. Of note, all HIV-positive patients presenting with PHeL had CD4 counts of less than 300 cells/µL at the time of diagnosis, emphasizing the degree of immunodeficiency seen in this patient population. Concomitant chronic infectious liver disease was also identified in this study, albeit at lower levels than HIV infection, approximately 16% for 
